IMPERIAL ENTERPRISE DIVISION
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From IMPERIAL ENTERPRISE DIVISION
Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.
Daphne Zohar tells Scrip PureTech will use $100m placing to develop Boston-based group's growth-stage affiliates and advance its "BIG" proprietary pipeline of brain-immune-gut assets.
Cambridge University spin-out Inivata has launched a major US clinical validation study to evaluate its liquid biopsy approach against tissue-based diagnostic methods in non-small cell lung cancer patients.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced November through December 2015.
- Academic and Research Institutions
- Other Names / Subsidiaries
- Imperial Innovations Group PLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.